Navigation Links
LUTRONIC® Finalizes Multi-System SPECTRA™ Deal with Unink, a Leading Tattoo Removal Chain in USA
Date:7/31/2013

Fremont, CA (PRWEB) July 31, 2013

LUTRONIC®, a global leader of lasers and therapeutic devices for aesthetic and medical applications, announced today the finalization of a multi-system SPECTRA™ deal with Unink Tattoo Removal, a leading tattoo removal chain in the USA.

Unink chose the Lutronic Spectra, a dual mode Q-switched Nd:YAG laser, because of its versatile and efficacious removal of multi-color tattoo inks. It offers four distinct wavelengths: 1064 nm, 532 nm and delivered via dye handpieces 585 nm and 650 nm. These options can target a wide variety of ink colors, including but not limited to black, red, green, blue and orange. Physicians and patients alike are impressed with the clearance achieved by the Spectra system. The technology behind the Spectra laser makes it truly unique; starting with the top-hat beam profile, which eliminates hotspots and true nanosecond pulse width, the system is developed for consistent outcomes and efficacious treatments.

“We are happy to have the right solution for the Unink Tattoo Removal franchise and are looking forward to many years of successful partnership,” shared Mark Merritt, USA Sales Director at Lutronic. “Our systems are reliable, effective, and backed by an outstanding support team. Ultimately, it is the patients who will truly benefit.”

Unink is a nationwide franchise with multiple locations and aggressive plans for expansion into new markets. By specializing exclusively in tattoo removal, the Unink technicians can focus on providing their patients with the best, most efficient treatment options at affordable prices.

“After a lot of thought and technology evaluation, Unink is proud to partner with Lutronic and choose the Spectra laser for all of our Tattoo removal clinics,” stated Stephen Heusinger, Chief Executive Officer of Unink Tattoo Removal. “Due to our high volume clinics we had to choose a partner that had a very effective system with proven reliability and superior clinical results. When we compared the product, service, training and support of Lutronic with other laser technology options, it became very clear that Lutronic and the Spectra was the right choice.”

About SPECTRA
LUTRONIC’s Dual-pulsed Q-switched Nd:YAG SPECTRA™ laser has been engineered to meet the growing demands of a busy clinic, and includes a variety of efficacious treatment options, customizable parameters, built-in safety and minimized downtimes, all at an affordable price.

With four distinct Q-switched mode wavelengths - 1064 nm, 532 nm, 585 nm, 650 nm, the robust Spectra has the versatility to provide your practice with a wide range of clinical options for treating your patients. Lutronic continually expands its treatment applications; and Spectra is the first Q-switched Nd:YAG laser cleared for the treatment of melasma. The technically advanced Spectra system offers an edge over other lasers and provides enhanced clinical outcomes.

To learn more about the Spectra please visit: http://www.lutronic.com/SPECTRA.

About LUTRONIC
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 15 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, skin resurfacing, body/facial contouring, chronic pain and more.

With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 130 current and pending patents worldwide. With more than 230 employees worldwide, Lutronic has offices in the US, Korea, China, Japan, and Europe, a worldwide network of distributors, and is ever expanding.

Learn More: http://www.lutronic.com

About UNINK Tattoo Removal
Unink Tattoo Removal is recognized as the fastest growing chain of tattoo removal clinics in the United States. The company is headquartered in Dallas, Texas, and backed by an investment firm with over 15 years of experience in healthcare sector investments. For investor or press information, contact Unink at 855-Ink-Away (855-465-2929), or Stephen Heusinger, CEO at sheusinger(at)unink(dot)com.

Learn more: http://www.uninktattooremoval.com

Contact:
Tracy Evleshin
Global Marketing Communications Director
850 Auburn Ct., Fremont CA 95134

Read the full story at http://www.prweb.com/releases/2013/7/prweb10985957.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lutronic® Announces FDA Clearance for INFINI™, an Ideal Solution for Wrinkle Reduction Through 3-D Volumization
2. Cloud Medical Doctor Software Corporation Finalizes Acquisition of Doctors Network of America and Expands its Medical Billing Services West
3. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
4. Diabetes drug could treat leading cause of blindness
5. Pneumonia and preterm birth complications are the leading causes of childhood death
6. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
7. Dr. Edmund Lipskis & Dr. Lynn Lipskis Will be Featured On New National Television Show Entitled: “Leading The Field” World Class Experts Share Their Tips & Advice
8. ACR: Medical imaging study in health affairs incomplete and potentially misleading
9. Poorly-performing hand implants unacceptable says leading medical journal
10. Leading cancer specialists from Europe and beyond recognized at ESMO 2012
11. WSU researchers discover mechanism leading from trichomoniasis to prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: